AGENITY

AGENITY is a Polish anti-ageing skincare brand developed by the Dr Irena Eris Centre for Science and Research, the laboratory arm of the cosmetics company Dr Irena Eris SA [2]. Marketed as a dermocosmetic line for sensitive skin, it is built around a patented growth-factor technology the company calls FGF1 LMS, paired with a delivery system named LIPO-SPHERE. The brand trades under the tagline "Patent for Beauty" [1].

It is a recent addition to its parent's portfolio. Dr Irena Eris SA, founded in 1983 by the pharmacist Irena Eris and her husband Henryk Orfinger, is among the most recognised cosmetics companies in Poland [4]; AGENITY does not appear in Wikipedia's list of the group's main brands, which points to a launch after that entry was written [5]. The brand was visible in Polish retail and editorial coverage through 2025 [6].

AGENITY is owned by Dr Irena Eris SA, a joint-stock company headquartered in Piaseczno, near Warsaw [5]. The parent was established in 1983 and is run as a family business; as of 2019 its board was led by Paweł Orfinger, son of the founders, while Irena Eris herself has continued to direct research and development [4]. The group operates its own Research and Development Centre, opened in 1999 in Warsaw, and markets several other lines including Pharmaceris and Lirene. AGENITY sits apart from those as a separate dermocosmetic brand rather than a renamed existing range.

The line is organised into a set of named series, each aimed at a different stage of ageing skin: Hydra-Ox for hydration, Retivine for wrinkles, Menoperfect for menopause-related changes, ProLift for lifting and firmness, Neuroglow for older skin, plus cleansing (Balance) and protective products. Individual items include the Retivine 2° Anti-Wrinkle Night Cream, the ProLift 4° Lifting Day Cream, the Age-Shield Multi-Protective Cream, and the Neuroglow 5° Rejuvenating Cream, which the company describes as a line for mature skin aged 65 and over.

At the centre of the range is a proprietary growth-factor technology the brand markets as FGF1 LMS, combined with a transdermal delivery system it calls LIPO-SPHERE. According to the company, the FGF1 LMS factor stimulates the activity of fibroblasts and keratinocytes — cells involved in maintaining skin structure — while the LIPO-SPHERE system carries active ingredients into deeper layers of the skin, which it states clinical testing has measured at up to 90 micrometres [2]. Other ingredients named across the range include two forms of retinol, peptides and vitamin E. Dr Irena Eris presents the formula as the work of Polish scientists and describes its safety and efficacy as confirmed by multi-centre clinical trials on highly sensitive skin.

AGENITY products are described as 100% vegan, with two stated exceptions, and the brand says its packaging is FSC-certified [1]. Its parent company has reported broader sustainability measures, including 87% recyclable packaging as of 2020 and membership of the UN Global Compact since 2016.

The brand positions itself as science-led anti-ageing skincare for sensitive and irritation-prone skin, with formulas intended for every stage of life from the first signs of ageing to mature skin [2]. It is sold as a high-end line: Polish pharmacy editorial has placed its products in a range of roughly 48 to 174 złoty (about 12 to 44 US dollars), describing it as a high-end cosmeceutical range [7]. Distribution is through pharmacies, both physical and online, and AGENITY maintains a dedicated information section for pharmacists [2].

As a recent and regionally focused brand, AGENITY has limited independent coverage. A Polish beauty blog, W Blasku Marzeń, published an editorial review of several products in the range in August 2025 [6], and the Polish pharmacy chain Ziko Dermo has published an article on the FGF1 LMS technology [7]. No major international beauty press coverage has been identified.

AGENITY is an active brand. Its most recent confirmed activity is the August 2025 Polish editorial coverage, consistent with a current retail presence [6]. Distribution appears limited to the Polish market, through Polish pharmacies and online drugstores; no Nordic availability has been identified, although the parent company is distributed in several other markets.